Drug Discovery World

JUNE 6, 2024

Professor Charles Swanton, Cancer Research UK’s chief clinician, said the melanoma trial results were “extremely impressive”, adding: “The new vaccine approach is another piece of the puzzle that will allow more patients to be cured, hopefully, or fewer patients to suffer disease relapse. months after initial treatment.

Vaccine 147

Vaccine Clinical Trials FDA Approval Research Laboratories 147

Drug Discovery World

SEPTEMBER 25, 2024

Mylotarg was ahead of its time in many ways: its novel structure of an antibody to target diseased cells, plus a cancer-killing payload attached via a special linker, is the blueprint for the antibody-drug conjugates (ADCs) that followed.

Therapies 162

Therapies Pharma Companies FDA Approval FDA 162

The Pharma Data

FEBRUARY 24, 2022

Food and Drug Administration approved Jardiance (empagliflozin) to reduce the risk of cardiovascular death and hospitalization for heart failure in adults. Jardiance was originally approved by the FDA in 2014 as a supplement to diet and exercise to improve glucose control in adults with type 2 diabetes.

FDA Approval 52

FDA Approval FDA Treatment Hospitals 52

Drug Discovery World

AUGUST 24, 2023

It is approved in adult patients who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. The CMA was supported by positive results from the Phase I/II MonumenTAL-1 study), in which 60.8%

FDA Approval 130

FDA Approval Therapies Hospitals Disease 130

PLOS: DNA Science

SEPTEMBER 5, 2024

A Brief History of Targeted Cancer Drugs In 1978, FDA approved the first targeted cancer drug, tamoxifen. The FDA approved Herceptin , targeting a different receptor (HER2) in breast cancer cells, in 1998. Keytruda illustrates more recently approved cancer drugs.

Treatment 52

Treatment FDA Approval DNA Small Molecule 52

The Pharma Data

MAY 26, 2023

Pfizer’s PAXLOVID™ receives FDA approval for adult patients at high risk of progression to severe COVID-19 Pfizer Inc. million treatment courses of PAXLOVID have been prescribed in the U.S. “Today marks a monumental milestone as PAXLOVID became the first COVID-19 oral treatment to be approved by the U.S.

FDA Approval 40

FDA Approval FDA Hospitals Vaccine 40

Drug Target Review

FEBRUARY 21, 2024

This is a time when several promising treatments – including mRNA vaccines, BiTE therapies and CAR-T cell therapy, are essentially in competition with each other – they all have a common goal of treating the same disease, but they are approaching the objective from different angles.

Therapies 64

Therapies Treatment FDA Approval Vaccine 64

Drug Target Review

AUGUST 29, 2024

MR : Chimeric antigen receptor T-cell (CAR-T) therapy is very effective in treating patients with B-cell lymphoma, leukemia, and multiple myeloma, where we have six FDA-approved drugs. However, these treatments will eventually fail for the majority of patients, so there is a strong need for better CAR therapies.

Therapies 59

Therapies Treatment Engineering Molecular Biology 59

The Pharma Data

JULY 12, 2021

Food and Drug Administration (FDA) has approved finerenone, the first non-steroidal, selective mineralocorticoid receptor (MR) antagonist, under the brand name Kerendia ®. Chronic kidney disease (CKD) is a common and potentially deadly condition that is generally underrecognized. Bayer announced today that the U.S.

FDA Approval 52

FDA Approval Disease FDA Treatment 52

The Pharma Data

JANUARY 20, 2021

FDA Approves Verquvo (vericiguat) for Heart Failure with Reduced Ejection Fraction. Patients with symptomatic chronic heart failure and reduced ejection fraction have a high risk for hospitalization after experiencing symptoms of heart failure requiring outpatient IV diuretic treatment or hospitalization.

FDA Approval 52

FDA Approval FDA Hospitals Treatment 52

The Pharma Data

APRIL 19, 2022

Food and Drug Administration (FDA) has approved commercial production at the company’s new CAR T-cell therapy manufacturing facility in Frederick, Maryland. The site will produce Kite’s FDA approved CAR T-cell therapy used to treat blood cancer. Gilead Sciences, Inc. Source link: [link].

FDA Approval 52

FDA Approval Therapies FDA Hospitals 52

Drug Discovery World

SEPTEMBER 7, 2023

Over 100 subtypes of childhood cancer exist today and it represents the most common cause of disease-related death in children. This could have profound impacts on end-stage patients who have previously had little or no treatment options.

Clinical Trials 147

Clinical Trials Trials Drugs DNA 147

The Pharma Data

NOVEMBER 20, 2020

FDA Approves Zokinvy (lonafarnib) for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies. Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the U.S. PALO ALTO, Calif.,

FDA Approval 52

FDA Approval FDA Clinical Trials Disease 52

The Pharma Data

MAY 5, 2021

Farxiga use expanded for reducing risks in patients with chronic kidney disease. Approval of the sodium-glucose cotransporter 2 (SGLT2) inhibitor was based on efficacy findings in the interventional, multicenter, randomized Dapa-CKD study. controlled trial had not received previous systemic therapy for metastatic disease.

FDA Approval 52

FDA Approval FDA Pharmacokinetics Therapies 52

The Pharma Data

APRIL 4, 2022

If approved, Actemra/RoActemra would be the first U.S. FDA approval is expected in the second half of this year. The sBLA submission is based on results from four randomised, controlled studies that evaluated Actemra/RoActemra for the treatment of COVID-19 in more than 5,500 hospitalised patients. A decision on U.S.

Treatment 52

Treatment FDA Approval Clinical Trials FDA 52

The Pharma Data

DECEMBER 12, 2020

. “The FDA’s authorization for emergency use of the first COVID-19 vaccine is a significant milestone in battling this devastating pandemic that has affected so many families in the United States and around the world,” FDA Commissioner Dr. Stephen Hahn said in a statement released Friday.

Vaccine 52

Vaccine FDA Approval FDA Nurses 52

The Pharma Data

JULY 29, 2021

Food and Drug Administration (FDA) has broadened the Emergency Use Authorization (EUA) for baricitinib to allow for treatment with or without remdesivir, whereas the EUA was previously restricted to use only in combination with remdesivir. percent (24/515) for baricitinib plus remdesivir versus 7.1 Wesley Ely, M.D.,

Hospitals 52

Hospitals FDA Laboratories Treatment 52

The Pharma Data

SEPTEMBER 1, 2021

Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Results found that 92.5 Click here to learn more: [link].

FDA Approval 52

FDA Approval FDA Treatment Clinical Trials 52

The Pharma Data

AUGUST 11, 2020

Photo by FDA/CDC. Gilead Sciences has asked the FDA to approve its drug remdesivir to treat COVID-19 patients. The treatment is already available on an emergency basis for people suffering with severe symptoms from coronavirus. The drug would go under the brand name of Veklury.

FDA Approval 52

FDA Approval FDA Government Virus 52

The Pharma Data

DECEMBER 29, 2020

29, 2020 /PRNewswire/ — Phase 3 program in hospitalized patients to continue based on passing futility analysis on ability to reduce incidence of death or mechanical ventilation. First antibody therapy to demonstrate anti-viral effect in patients hospitalized with COVID-19. TARRYTOWN, N.Y. , Regeneron Pharmaceuticals, Inc.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

The Pharma Data

JULY 8, 2021

ADUHELM should be initiated in patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia. Food and Drug Administration (FDA) has approved an updated label for ADUHELM (aducanumab-avwa) injection 100 mg/mL solution. ADUHELM is indicated for the treatment of Alzheimer’s disease.

Clinical Trials 52

Clinical Trials FDA Approval Trials FDA 52

Broad Institute

FEBRUARY 8, 2024

Researchers uncover genetic factors for severe Lassa fever By Allessandra DiCorato February 8, 2024 Breadcrumb Home Researchers uncover genetic factors for severe Lassa fever New findings from an international collaboration pave the way for studies of highly infectious diseases in Africa such as Ebola. Chan School of Public Health.

Research 81

Research Virus Hospitals Disease 81

The Pharma Data

MAY 31, 2022

The approval is based on interim efficacy and safety data from the RAINBOWFISH study in newborns, which showed that the majority of pre-symptomatic babies treated with Evrysdi achieved key milestones such as sitting and standing with half walking after 12 months of treatment. Jude Children’s Research Hospital.

FDA Approval 52

FDA Approval FDA Treatment Clinical Trials 52

The Pharma Data

DECEMBER 3, 2020

“ORLADEYO offers people with HAE and their physicians the first orally administered non-steroidal option for preventing HAE attacks and represents an important and welcome step in making more treatment options available to physicians and patients,” said Anthony J. attacks per month at baseline, to a mean of 1.0 attacks per month.

FDA Approval 52

FDA Approval Therapies FDA Trials 52

The Pharma Data

NOVEMBER 25, 2020

November 25, 2020 — Under FDA law, approval of a new drug requires substantial evidence of effectiveness and a demonstration of safety for the drug’s intended use(s). The approval of remdesivir ( Veklury ) for the treatment of patients hospitalized with COVID-19 met this legal and scientific standard.

FDA 52

FDA Treatment Hospitals Clinical Trials 52

The Pharma Data

DECEMBER 17, 2020

(NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. “The investigational cocktail is now available to indicated high-risk U.S.

Hospitals 52

Hospitals Production Clinical Trials Virus 52

The Pharma Data

DECEMBER 16, 2020

Food and Drug Administration (FDA) has approved Benlysta to treat lupus nephritis (lupus-related kidney disease) in adults. The approval is for both the intravenous and subcutaneous formulations. Up to 60 percent of people with lupus will develop lupus nephritis. ” Dr. Susan M.

FDA Approval 52

FDA Approval FDA Clinical Trials Treatment 52

The Pharma Data

DECEMBER 21, 2020

Food and Drug Administration (FDA) has now approved the very first oral drug to treat the millions of men affected. . We know from our research that the majority of men prefer an oral treatment to an injection,” Myovant CEO Lynn Seely said. It’s, we believe, one of the reasons we were granted priority review by the FDA.” .

FDA Approval 52

FDA Approval FDA Therapies Drugs 52

The Pharma Data

AUGUST 28, 2020

The top 10 news stories this week are focused on coronavirus vaccines and treatments, as China is set to move ahead with human testing of a potential vaccine that has been created using insect cells, while AstraZeneca has started a clinical trial of its antibody treatment designed to prevent and also treat symptoms of coronavirus.

FDA Approval 52

FDA Approval Clinical Trials Vaccine FDA 52

The Pharma Data

APRIL 6, 2021

Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for baricitinib for the treatment of adults with moderate to severe atopic dermatitis (AD). OLUMIANT is a once-daily, oral JAK inhibitor approved in the U.S. WARNING: SERIOUS INFECTIONS, MALIGNANCY, AND THROMBOSIS.

Treatment 52

Treatment Clinical Trials Drugs Therapies 52

Drug Discovery World

JULY 2, 2024

Zurich: The financial centre Life science park Bio-Technopark Schlieren-Zürich benefits from close proximity to the Swiss Federal Institute of Technology (ETH), the University and Zurich University Hospital. In 2005, Glycart was acquired by the Roche Group and integrated in Roche Pharma Research and Early Development (pRED).

Science 147

Science Drugs Clinical Trials Licensing 147

Drug Discovery World

APRIL 14, 2023

He is being recognised for his revolutionary contributions to developing the first gene-edited cell-based therapy for cancer that involves the genetic re-engineering of a patient’s own T cells to combat their disease, and for demonstrating that adoptive T-cell therapy can induce remission and in some cases cure patients with advanced cancer.

Clinical Trials 130

Clinical Trials Research Science Clinical Research 130

The Pharma Data

OCTOBER 30, 2020

NASDAQ: REGN) received today a recommendation from the independent data monitoring committee (IDMC) for the REGN-COV2 antibody cocktail treatment trials for COVID-19 that the current hospitalized patient trial be modified. About the REGN-COV2 Trial in Hospitalized Patients. Regeneron Pharmaceuticals, Inc.

Hospitals 52

Hospitals Virus Production Clinical Trials 52

The Pharma Data

NOVEMBER 20, 2020

20, 2020 — Emergency use authorization was issued for baricitinib in combination with remdesivir for hospitalized patients with COVID-19, the U.S. The janus kinase inhibitor baricitinib is currently FDA-approved for treating moderately to severely active rheumatoid arthritis. FRIDAY, Nov. More Information.

FDA 52

FDA FDA Approval Hospitals Clinical Trials 52

Codon

AUGUST 26, 2024

One large-scale clinical trial found that it only reduces the relative risk of death by about ten percent in hospitalized patients. If we’re unlucky, however, our immune system goes into overdrive even as viral load subsides, causing damage to our lungs and sending us to the hospital. Unsubscribe any time.

RNA 87

RNA Virus DNA Vaccine 87

The Pharma Data

OCTOBER 26, 2020

FDA Actions. FDA Approval: Last week the FDA approved Veklury (remdesivir) for the treatment of COVID-19 requiring hospitalization in adults and pediatric patients (12 years of age and older). Eli Lilly halted a separate study of its LY-COV555 antibody against COVID-19 in hospitalized patients.

Vaccine 52

Vaccine FDA Approval FDA Clinical Trials 52

The Pharma Data

OCTOBER 22, 2020

October 22, 2020 — In less than one year, the world has moved from a sense of desperation to understand an unknown disease spreading all too quickly and taking lives, to one of hope that we now have enough knowledge and a growing set of tools to help fight COVID-19.

Science 52

Science Clinical Trials Hospitals FDA Approval 52